Comparative Pharmacology
Head-to-head clinical analysis: AEROLONE versus THEO 24.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLONE versus THEO 24.
AEROLONE vs THEO-24
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Theophylline, a xanthine derivative, acts as a non-selective phosphodiesterase (PDE) inhibitor (primarily PDE3 and PDE4), increasing intracellular cAMP and cGMP in airway smooth muscle and inflammatory cells. It also antagonizes adenosine receptors (A1, A2), stimulates endogenous catecholamine release, and may enhance histone deacetylase activity, reducing inflammation.
AEROLONE is not a recognized drug; no standard dosing available.
300-600 mg orally once daily, extended-release capsule; individualize based on serum theophylline concentration targeting 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 3–8 hours in adults (non-smokers), 4–5 hours in smokers (due to enzyme induction), and highly variable in neonates (24–36 hours) and children (1–9 hours). Half-life is prolonged in cirrhosis (up to 30 hours), heart failure, and with concomitant medications (e.g., cimetidine, erythromycin).
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Approximately 90% of theophylline is eliminated hepatically via metabolism (principally CYP1A2 and CYP3A4), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug is minimal (about 5%) in adults. Biliary/fecal excretion accounts for less than 1%.
Category C
Category C
Bronchodilator
Bronchodilator